CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities research analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($1.48) per share for the quarter, down from their previous estimate of ($1.47). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.17) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.
CRSP has been the subject of several other reports. Barclays reduced their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Wednesday. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $77.93.
CRISPR Therapeutics Stock Down 5.0 %
Shares of CRSP opened at $45.40 on Thursday. CRISPR Therapeutics has a twelve month low of $43.42 and a twelve month high of $91.10. The stock has a market capitalization of $3.88 billion, a P/E ratio of -16.04 and a beta of 1.62. The company has a 50 day moving average of $48.83 and a 200-day moving average of $51.29.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the business earned ($1.41) EPS.
Institutional Investors Weigh In On CRISPR Therapeutics
Institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC lifted its position in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the period. GPS Wealth Strategies Group LLC lifted its position in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics during the second quarter worth about $35,000. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $43,000. 69.20% of the stock is currently owned by institutional investors.
Insider Buying and Selling at CRISPR Therapeutics
In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,382 shares of company stock valued at $2,744,179 in the last ninety days. 4.10% of the stock is currently owned by corporate insiders.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
- Five stocks we like better than CRISPR Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- What to Know About Investing in Penny Stocks
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.